Production & Sales

Samsung Biologics signs $1.24bn manufacturing deal with Asian pharma company

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has secured a contract manufacturing deal valued at $1.24bn with an Asia-based pharmaceutical company.

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

ENCell has entered into a strategic alliance and licencing agreement with Lucy Biotech for EN001, a next-generation mesenchymal stem cell therapy.

Merck introduces single-use reactor to accelerate ADC manufacturing

German company Merck has introduced the first single-use reactor specifically designed for the production of antibody-drug conjugates (ADCs).

Novartis begins construction works at two RLT manufacturing facilities in US

Novartis has announced the commencement of construction on two new radioligand therapy (RLT) manufacturing facilities in the US, in a bid to expand its production and supply chain capabilities in the sector.

RedHill launches Talicia in UAE to treat H. pylori infection

RedHill Biopharma has launched Talicia in the UAE, a treatment option for adults with Helicobacter pylori (H. pylori) infection.

Merck launches GMP-compliant cell culture media line in China

Merck has initiated commercial manufacturing of its first Good Manufacturing Practices (GMP)-compliant manufacturing line for cell culture media (CCM) in China.

Rosemont acquires Pharma-Data to enhance global product development

Rosemont Pharmaceuticals, a developer of liquid medicines, has announced the acquisition of Pharma-Data, a research and development organisation based in Lavrion, Greece, enhancing its ability to develop products for worldwide market.

Amneal Pharmaceuticals launches supply of Naloxone HCI Nasal Spray in US

Amneal Pharmaceuticals has initiated the distribution of its over-the-counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, to retail pharmacies across the US, including the State of California.

Sol-Gel, Beimei sign deal for TWYNEO commercialisation

Sol-Gel Technologies has entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical, granting the latter exclusive rights to commercialise Sol-Gel’s dermatology product TWYNEO in mainland China, Taiwan, Hong Kong, Macau, and Israel.